An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma

Study Status

Open to Enrollment

Study Description

This clinical trial is for people with lymphoma and for whom standard drugs for the lymphoma are not working. The study is testing an experimental drug called MLN9708.

The purpose of the study is to determine:

  • The side effects and risks of the study drug
  • The highest dose of MLN9708 that can be given to people with lymphoma without causing side effects that are too severe
  • How MLN9708 influences cancer cells and how they grow
  • How your body processes MLN9708

All study participants will receive MLN9708. There is no placebo. The study will enroll participants into different dose levels. The study drug will be given in 28 day cycles: Days 1, 8 and 15 of each cycle via infusion. Days 16 through 28 are a rest period.

The length of time on study will depend on how a participant is feeling, how well they tolerate the study drug, and how well their lymphoma responds to MLN9708.

Disease Status and/or Stage

Relapsed or Refractory Lymphoma (non-Hodgkin and Hodgkin)

Sponsor

Millennium

Key Eligibility

  • Men and women age 18 and older
  • Relapsed/refractory lymphoma (non-Hodgkin and Hodgkin) after at least 2 chemotherapy regimens
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Peter Martin, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page